1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. California >
  6. Cumberland Pharmaceuticals Acquires Theravance Biopharma - VIBATIV

M&A Deal Summary

Cumberland Pharmaceuticals Acquires Theravance Biopharma - VIBATIV

On November 6, 2018, Cumberland Pharmaceuticals acquired life science company Theravance Biopharma - VIBATIV from Theravance Biopharma for 20M USD

Acquisition Highlights
  • This is Cumberland Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Cumberland Pharmaceuticals’ largest (disclosed) transaction.
  • This is Cumberland Pharmaceuticals’ 1st transaction in the United States.
  • This is Cumberland Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2018-11-06
Target Theravance Biopharma - VIBATIV
Sector Life Science
Buyer(s) Cumberland Pharmaceuticals
Sellers(s) Theravance Biopharma
Deal Type Divestiture
Deal Value 20M USD

Target

Theravance Biopharma - VIBATIV

South San Francisco, California, United States
Theravance Biopharma, Inc. - VIBATIV is patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin & skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Cumberland Pharmaceuticals

Nashville, Tennessee, United States
Category Company
Founded 1999
Sector Life Science
Employees91
Revenue 38M USD (2024)
DESCRIPTION

Cumberland Pharmaceuticals is a pharmaceutical company that acquires and develops branded prescription products primarily in the gastroenterology, critical care and infection control areas. Cumberland Pharmaceuticals was founded in 1999 and is based in Nashville, Tennessee.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Theravance Biopharma

South San Francisco, California, United States
Category Company
Founded 2013
Sector Life Science
Employees97
Revenue 64M USD (2024)
DESCRIPTION

Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance Biopharma was founded in 2013 and is based in George Town, Caymen Islands.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 2
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Size (of disclosed) 2 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-06-02 Trelegy Ellipta

London, United Kingdom

Trelegy Ellipta is a prescription inhaled medication formulated for the long-term maintenance treatment of chronic obstructive pulmonary disease, including emphysema and chronic bronchitis, and, in some instances, for asthma in adults. Trelegy Ellipta is based in London, United Kingdom.

Sell $225M
Mergr

Solution for

Product

Company

Legal